Artificial Intelligence
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer.
“I am excited to join Qu as the company prepares to initiate multiple phase 2 randomized placebo-controlled studies,” said Dr. Cahill. “The Qu platform has the potential to make a profound impact in indications across oncology, inflammation, and infectious disease, and I look forward to supporting the growth of the organization and the expansion of our clinical pipeline.”
Prior to joining Qu, Matt was a founding employee of Deep Genomics – a biotechnology company focused on the application of artificial intelligence in drug development. He played a central role in crafting and operationalizing the company’s strategy, helped build the executive team, and led a variety of functions including finance, legal, HR, and business development. During his tenure, the company formed its first Pharma partnerships and raised more than USD$200M through multiple rounds of financing.
Matt received his JD and MBA from the University of Toronto with an emphasis on biotechnology, entrepreneurship, and strategy. He received his PhD from the University of Cambridge, where he studied the genomes of bacteria using novel sequencing technologies.
“The Qu team and I are delighted to welcome Matt as COO at this critical time in Qu’s history, and we look forward to working together,” said Dr. Hal Gunn, CEO of Qu Biologics. “His post-graduate degrees in science, law, and business and his past demonstrated success leading biotech finance, business development, and operations make him an excellent match for our needs as we enter the important next phase of our mission to realize the full potential of SSIs.”
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.
Please subscribe here to receive future news and updates from Qu Biologics.
About Qu Biologics
Qu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to restore innate immune function in targeted organs to reverse the immune dysregulation underlying many important diseases including cancer, chronic inflammatory diseases, and infection. Qu Biologics has completed four Phase 2 studies in lung cancer, Crohn’s disease, and ulcerative colitis. Two additional Phase 2 randomized placebo-controlled studies, in late-stage colon cancer and immunosenescence, have received regulatory and ethics approval.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; Chief Medical Officer – Oncology Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally; Chief Medical Officer – Infectious Disease Dr. Ted Steiner, a clinician-scientist specializing in immune responses to infections and Head of the UBC Division of Infectious Diseases; and COO Dr. Matt Cahill, an accomplished biotech executive with experience financing and scaling platform biotechnology companies. For more information, please visit www.qubiologics.com.
Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.
Artificial Intelligence
THE 2024 GLOBAL EXPLORATION SUMMIT IS ANNOUNCED AT THE 120th EXPLORERS CLUB ANNUAL GALA IN NEW YORK
Porto and Terceira Island to Host the ‘Davos of Exploration’ – The GLEX Summit
NEW YORK, April 24, 2024 /PRNewswire/ — The Explorers Club and Expanding World, are thrilled to announce the fifth edition of The GLEX Summit, known as the ‘Davos of Exploration,’ set to take place from June 15 to 19 on Porto city and Terceira Island in the Azores, Portugal.
This year, Porto will Ignite the summit, followed by two days of discussions and exploration in the historic city of Angra do Heroísmo on Terceira Island. From the depths of the oceans to new space missions, the power and future of exploration will be explored in these two World Heritage cities, deeply connected to the history of exploration.
The 2024 GLEX Summit will revolve around the latest discoveries and groundbreaking missions shaping the future of our planet. Highlights of the summit include the Artemis mission, which plans to send astronauts back to the moon for the first time since 1972, and the role of Space and the Oceans in researching and mitigating the effects of climate change. Notable sessions will also delve into the unfortunate incident of the submersible implosion that took place on Titan and the recording of an episode of the BBC’s acclaimed science comedy show ‘The Infinite Monkey Cage,’ hosted by physicist Brian Cox and comedian Robin Ince.
This prestigious event will bring together over three dozen explorer and scientist legends from around the world. Confirmed physicist and researcher Brian Cox, NASA Chief Scientist James Garvin, Aquanaut Fabien Cousteau, Oceanographer David Gallo, Cosmonaut Mike Massimino, Nasa ISS CapCom Tess Caswell, among many others global Explorers and Scientists.
For further inquiries about The GLEX Summit and press accreditation, please contact:
Marco Barbosa [email protected], +351917345744
Photo: https://mma.prnewswire.com/media/2395857/GLEX_Summit.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/the-2024-global-exploration-summit-is-announced-at-the-120th-explorers-club-annual-gala-in-new-york-302125563.html
Hillstone Networks delivers advanced Microsegmentation across different verticals..
SANTA CLARA, Calif., April 24, 2024 /PRNewswire/ — Hillstone Networks, a leading provider of cybersecurity solutions, has been included in the Forrester Microsegmentation Solutions Landscape, Q2 2024 report. The report offers an overview of the Microsegmentation market, focused on the vendors who deliver solutions for protection of critical resources, combating ransomware, and contributing to compliance adherence. The report provides security professionals a snapshot of these named vendors, considering factors such as size, geographic focus, and use cases to select the most suitable option for their targeted use cases or needs.
In the Landscape Report, Forrester states that “Zero Trust is all about replacing bodies of implicit trust with explicit policy. In physical and virtual networks, the application of this principle is referred to as microsegmentation…. [It] was one of the first true Zero Trust technologies developed after Forrester published the initial Zero Trust reports.”
Forrester states in the report that the main trend is “organizations are finally getting serious about Zero Trust. Some, proactively, are implementing microsegmentation as part of a Zero Trust strategy or initiative. Others are implementing it because they got hit by ransomware and are trying to avoid it again. But all of them are doing Zero Trust with microsegmentation.”
“Being recognized as a vendor in the Microsegmentation solution landscape underscores for us the pivotal role our technology plays in safeguarding critical assets and thwarting ransomware threats. We believe it reaffirms our commitment to providing cutting-edge security measures built on an innovative and AI-powered platform that help our customers defend against evolving cyber risks, ensuring resilience and trust,” states Tim Liu, CTO and Co-founder at Hillstone Networks.
Hillstone’s Microsegmentation solution provides the following key benefits:
Advanced and extensive Microsegmentation for physical servers, virtual machines, cloud hosts, and containers, seamlessly compatible with multiple platforms.Comprehensive, integrated Layer 4 to 7 security and malware features (Next Generation Firewall, Intrusion Prevention System, AntiVirus, URL filtering, DDoS, and bot defense), and complete vulnerability management across the entire application lifecycle.Distributed architecture for easy scaling and portability.Centralized and comprehensive visibility to reduce gaps in the threat surface.Learn more about Hillstone Networks solutions here.
About Hillstone Networks
Hillstone Networks’ Integrative Cybersecurity approach is based on a visionary, AI-powered, and accessible platform, delivering coverage, control, and consolidation to secure over 28,000 global enterprises.
Media ContactZeyao Hu+1 [email protected]
Logo – https://mma.prnewswire.com/media/765968/Hillstone_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hillstone-networks-is-named-in-microsegmentation-solutions-landscape-report-302125530.html
Artificial Intelligence
Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System
The collaboration brings together Tetra Pharm Technologies’ expertise in enabling technology with Glysious’ proprietary transdermal drug delivery system, renowned for its effectiveness, comfort, and convenience.
COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ — Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds targeting the endocannabinoid system.
Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company’s incorporation in 2020.
“The Glysious technology enables precision, sustained dosing, and allows for a high drug load and effective emptying of patches. The transdermal patches remain in place and are very comfortable and convenient to use, resulting in improved patient compliance. However, we have identified challenges with standard formulation strategies, not providing acceptable drug release due to shortcomings of the formulation matrix”, says Professor, Dr.Techn. Anne Ladegaard Skov, Chief Scientific Officer, Glysious.
Back in 2023 Glysious and Tetra Pharm Technologies performed early in-vitro feasibility tests, integrating Tetra Pharma Technologies’ proprietary enabling technology for delivery of poorly soluble compounds with Glysious’ patch.
Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies, adds: “Although both parties were aware of the uniqueness of our respective technologies, we were positively surprised to find a five-fold increase in performance of our combination product compared to conventional formulation technologies. This is truly remarkable, and we consider it our shared obligation to further advance this technology to the benefit of the patients.”
The objectives of the collaboration include conducting comprehensive in-vitro and in-vivo studies to evaluate the performance and efficacy of the combined drug delivery system. Additionally, Tetra Pharm Technologies and Glysious plan to pursue a common patent for the joint invention, ensuring that their innovative technology remains protected and exclusive.
“We are excited to collaborate with the innovative team in Tetra Pharm Technologies on this transdermal drug delivery system paving the way for commercialization and scaling of the Glysious technology within the pharma segment”, says Stina Bjerg Nielsen, Chief Executive Officer, Glysious.
Martin Rose, Chief Executive Officer, Tetra Pharm Technologies, concludes: “The collaboration represents a unique opportunity to harness the synergies between our respective technologies. By combining our expertise, we aim to develop a transdermal drug delivery system that offers superior efficacy, convenience, and patient compliance, supporting several of our pipeline programs”.
As part of the collaboration, the partners will exchange expertise, knowledge, and resources. In addition, Tetra Pharm Technologies and Glysious will conduct joint research, experiments, and tests as required for the development of a joint patent. The scope of the collaboration is focused on disease indications such as pain, sleep disorders, and appetite regulation.
About Tetra Pharm Technologies
Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu
About Glysious
Glysious is a Danish medtech company, incorporated in 2020, that develops patches, creams, spray, and foams with controlled release of active ingredients for cosmetics and life science applications. For more information, please visit www.glysious.com
For further informationJacob SchlundtChief Marketing OfficerTetra Pharm [email protected]+45 51976225
Stina Bjerg NielsenChief Executive [email protected]+45 3053 5393
Photo – https://mma.prnewswire.com/media/2393210/Tetra_Pharm_Technologies_Deal.jpgLogo – https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system-302123136.html
-
Artificial Intelligence7 days agoHuawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Uncategorized5 days agoGenerative AI gold rush drives IT spending — with payoff in question
-
Uncategorized5 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized5 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized5 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence5 days agoFree Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized5 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized5 days ago
The Ottawa Hospital doctors to try AI for patient notes
